ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS

Clinical trials for ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS trials appear

Sign up with your email to follow new studies for ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug targets 'Undruggable' cancer mutation in early human trial

Disease control Recruiting now

This study is testing a new drug called FMC-376 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. It is for patients whose cancer ha…

Matched conditions: ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS

Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control

Last updated Mar 10, 2026 12:53 UTC

ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS

Get alerted when new ADVANCED SOLID TUMORS WITH KRAS G12C MUTATIONS trials appear

New drug targets 'Undruggable' cancer mutation in early human trial